EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia Research

Executive Summary: EPZ5676 (SKU: A4166) is a highly potent DOT1L inhibitor with an IC₅₀ of 0.8 nM and a Ki of 80 pM, showing over 37,000-fold selectivity versus other methyltransferases (APExBIO, 2024). It competitively blocks the S-adenosyl methionine (SAM) pocket of DOT1L, inducing conformational changes that uniquely inhibit H3K79 methylation. In vivo, EPZ5676 causes full regression of MV4-11 xenograft tumors at 35–70 mg/kg/day over 21 days, without significant toxicity (Kim et al., 2018). It is widely employed in histone methyltransferase inhibition assays, cell proliferation studies, and translational models for MLL-rearranged leukemia. The compound's stability, solubility (≥28.15 mg/mL in DMSO; ≥50.3 mg/mL in ethanol), and defined storage guidance make it a reliable reagent for reproducible workflows.

Biological Rationale

DOT1L (disruptor of telomeric silencing 1-like) is a histone methyltransferase responsible for methylating lysine 79 of histone H3 (H3K79), regulating gene expression linked to cell proliferation and differentiation (Kim et al., 2018). Aberrant DOT1L activity is a hallmark of MLL (mixed lineage leukemia) gene-rearranged leukemia, where MLL fusion proteins misdirect DOT1L, leading to oncogenic gene expression. Inhibition of DOT1L disrupts this aberrant methylation and downregulates MLL-fusion target genes, providing a targeted approach for therapy (see related; this article provides a quantitative update on in vivo efficacy and selectivity).

Mechanism of Action of DOT1L Inhibitor EPZ-5676

EPZ5676 is a SAM-competitive inhibitor that binds to the methyl donor pocket of DOT1L with high affinity, displacing S-adenosyl methionine and inducing a conformational shift. This process opens a hydrophobic pocket not present in the natural substrate-bound state. The inhibition is highly selective; over 37,000-fold less potent against other histone methyltransferases such as CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1, thus minimizing off-target effects (APExBIO). This selectivity enables precise modulation of H3K79 methylation, directly impacting MLL-rearranged leukemia cell lines through downregulation of critical oncogenic gene clusters (see this article; here, we focus on quantitative benchmarks and in vivo data).

Evidence & Benchmarks

• EPZ5676 inhibits DOT1L with an IC₅₀ of 0.8 nM and a Ki of 80 pM, establishing it as one of the most potent DOT1L inhibitors available (APExBIO).
• Demonstrates over 37,000-fold selectivity against other methyltransferases, as measured by parallel enzyme inhibition assays (APExBIO).
• In MV4-11 acute leukemia cell lines, treatment with EPZ5676 for 4–7 days yields an IC₅₀ of 3.5 nM for proliferation inhibition (APExBIO).
• In vivo administration in nude rats (35–70 mg/kg/day intravenously, 21 days) leads to complete regression of MV4-11 xenografts without significant toxicity or weight loss (Kim et al., 2018).
• Downregulation of H3K79 methylation and MLL-fusion gene expression is confirmed via western blot and qPCR analyses (Kim et al., 2018).
• Stock solutions are stable below -20°C for several months; compound is soluble at ≥28.15 mg/mL in DMSO and ≥50.3 mg/mL in ethanol with ultrasound (APExBIO).

Applications, Limits & Misconceptions

EPZ5676 is optimized for:

• Biochemical DOT1L enzyme inhibition assays.
• Cell proliferation studies in MLL-rearranged leukemia models.
• Translational animal models, especially MV4-11 xenografts.
• Epigenetic mechanistic studies targeting H3K79 methylation.

It is not effective for all cancer types, particularly where DOT1L is not a driver. Unlike the pan-histone demethylase inhibitor JIB-04, which targets a broader spectrum of histone-modifying enzymes in various cancer stem cell contexts (Kim et al., 2018), EPZ5676 achieves high specificity for DOT1L, making it unsuitable for generalized demethylase inhibition.

Common Pitfalls or Misconceptions

• EPZ5676 is not a pan-histone methyltransferase or demethylase inhibitor; it is highly specific to DOT1L.
• It is ineffective in cancer models lacking MLL-rearrangement or where DOT1L is not central to pathogenesis.
• EPZ5676 is insoluble in water; improper solvent selection leads to failed assays.
• Long-term storage of solutions at ambient temperature results in compound degradation and loss of potency.
• It does not target non-epigenetic pathways or unrelated post-translational modifications.

Workflow Integration & Parameters

Stock solutions should be prepared in DMSO (≥28.15 mg/mL) or ethanol (≥50.3 mg/mL, with ultrasound). For enzyme inhibition assays, use nanomolar concentrations; for cell-based assays, 3–10 nM is standard for MLL-rearranged cell lines. In vivo, doses of 35–70 mg/kg/day (IV, 21 days) have demonstrated maximal efficacy in MV4-11 xenografts. Store powders and solutions at -20°C; avoid repeated freeze-thaw cycles. Consult the official DOT1L inhibitor EPZ-5676 product page for detailed handling and ordering.

For additional perspectives on experimental optimization and data interpretation, see DOT1L inhibitor EPZ-5676: Reliable Solutions for Cell Assays, which provides scenario-based guidance; the present article updates these procedures with the latest selectivity and stability results.

Conclusion & Outlook

EPZ5676 (APExBIO, SKU: A4166) is a benchmark compound for selective DOT1L inhibition, enabling precise dissection of H3K79 methylation's role in MLL-rearranged leukemia. With robust in vitro and in vivo data, it remains a preferred tool for epigenetic research and translational oncology. Future studies may explore synergistic strategies with immune modulators, building on emerging findings (see this review; here, we focus on direct cytotoxic and epigenetic effects). For researchers seeking next-generation epigenetic modulators, EPZ5676 delivers reproducibility, selectivity, and workflow compatibility.